PL2604695T3 - Cząstka arenawirusa z defektem replikacji - Google Patents

Cząstka arenawirusa z defektem replikacji

Info

Publication number
PL2604695T3
PL2604695T3 PL13152727.7T PL13152727T PL2604695T3 PL 2604695 T3 PL2604695 T3 PL 2604695T3 PL 13152727 T PL13152727 T PL 13152727T PL 2604695 T3 PL2604695 T3 PL 2604695T3
Authority
PL
Poland
Prior art keywords
replication
arenavirus particle
defective arenavirus
defective
particle
Prior art date
Application number
PL13152727.7T
Other languages
English (en)
Inventor
Daniel David PINSCHEWER
Lukas Roland FLATZ
Andreas Bergthaler
Rudolf M. Zinkernagel
Original Assignee
Universität Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Zürich filed Critical Universität Zürich
Publication of PL2604695T3 publication Critical patent/PL2604695T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
PL13152727.7T 2007-12-27 2008-12-22 Cząstka arenawirusa z defektem replikacji PL2604695T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07025099 2007-12-27

Publications (1)

Publication Number Publication Date
PL2604695T3 true PL2604695T3 (pl) 2023-04-11

Family

ID=40428182

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13152727.7T PL2604695T3 (pl) 2007-12-27 2008-12-22 Cząstka arenawirusa z defektem replikacji
PL08868316T PL2238255T3 (pl) 2007-12-27 2008-12-22 Wektory arenawirusowe z defektem replikacji

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08868316T PL2238255T3 (pl) 2007-12-27 2008-12-22 Wektory arenawirusowe z defektem replikacji

Country Status (15)

Country Link
US (7) US8592205B2 (pl)
EP (3) EP4186978A1 (pl)
JP (3) JP5642556B2 (pl)
CN (3) CN103993012B (pl)
CA (1) CA2744910C (pl)
DK (2) DK2604695T3 (pl)
ES (2) ES2438773T3 (pl)
FI (1) FI2604695T3 (pl)
HR (1) HRP20221475T3 (pl)
HU (1) HUE061060T2 (pl)
LT (1) LT2604695T (pl)
PL (2) PL2604695T3 (pl)
PT (1) PT2604695T (pl)
SI (1) SI2604695T1 (pl)
WO (1) WO2009083210A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604695T3 (pl) 2007-12-27 2023-04-11 Universität Zürich Cząstka arenawirusa z defektem replikacji
EP2478103A4 (en) * 2009-09-16 2014-02-19 Univ Tulane LASSAVIRUS-like PARTICLES AND METHOD FOR THE PRODUCTION THEREOF
CN103068835A (zh) * 2010-06-06 2013-04-24 西奈山医学院 重组rna 病毒及其用途
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CN103687625B (zh) * 2011-07-11 2017-06-13 艾诺奥医药品有限公司 交叉保护性沙粒病毒疫苗及其使用方法
CN105473604B (zh) 2013-03-13 2021-01-22 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
ES2751423T3 (es) 2013-03-15 2020-03-31 Univ Geneve Vacunas antimicobacterianas
DK3077519T3 (en) * 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
WO2015123592A2 (en) 2014-02-13 2015-08-20 Synthetic Genomics, Inc. Recombinant rna particles and methods of use
US10836998B2 (en) 2014-02-14 2020-11-17 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
BR112017005744B1 (pt) 2014-09-22 2023-11-28 Regents Of The University Of Minnesota "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo"
HUE051390T2 (hu) 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
HK1246183A1 (zh) * 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2018045029A1 (en) * 2016-09-02 2018-03-08 The United States Of America, As Represented By The Secretary Of The Army Pan south american arenavirus live attenuated vaccine
CN115948467A (zh) 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
US11260090B2 (en) * 2016-03-08 2022-03-01 University Of Vermont And State Agricultural College Modified arenavirus
IL314272A (en) * 2016-05-18 2024-09-01 Hookipa Biotech Gmbh Three-segmented PICHINDE viruses as vaccine vectors
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
AU2020297011A1 (en) 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
EP4045672A4 (en) * 2019-10-18 2023-11-22 University of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR PRODUCING ENHANCED IMMUNE RESPONSES AND RAPID ANTIBODY PRODUCTION
US20220380805A1 (en) 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
KR20230131481A (ko) 2021-01-14 2023-09-13 길리애드 사이언시즈, 인코포레이티드 Hiv 백신 및 이의 사용 방법
BR112023019365A2 (pt) 2021-03-23 2023-12-26 Hookipa Biotech Gmbh Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit
US20240229073A1 (en) 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
JP2024540385A (ja) 2021-11-08 2024-10-31 ホオキパ バイオテック ジーエムビーエイチ 変異型ｋｒａｓ、変異したがんドライバー遺伝子、または腫瘍関連抗原を発現する、がん免疫療法としての改変アレナウイルス粒子
EP4475879A1 (en) 2022-02-08 2024-12-18 Hookipa Biotech GmbH Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
CN117343911A (zh) * 2022-06-28 2024-01-05 中国科学院上海药物研究所 一种缺陷型丝状病毒的制备方法及其应用
JP2025523043A (ja) 2022-07-12 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US7267823B2 (en) 1998-06-29 2007-09-11 United States Of America As Represented By The Secretary Of The Army Ebola peptides and immunogenic compositions containing same
DE19856463B4 (de) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
AU2002331572A1 (en) 2002-04-17 2003-11-03 Astropower, Inc. Maximum power sensor for photovoltaic system
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
WO2005061534A2 (en) 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
EA012037B1 (ru) 2004-11-16 2009-06-30 Круселл Холланд Б.В. Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
US20070005929A1 (en) * 2005-06-30 2007-01-04 Post Daniel J Method, system, and article of manufacture for sector mapping in a flash device
PL2604695T3 (pl) * 2007-12-27 2023-04-11 Universität Zürich Cząstka arenawirusa z defektem replikacji
EP2664680A1 (en) 2011-01-07 2013-11-20 Bioscience Slovakia Antibody-based methods of diagnosing infections with lymphocytic choriomeningitis virus (LCMV)
ES2751423T3 (es) 2013-03-15 2020-03-31 Univ Geneve Vacunas antimicobacterianas
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
HUE051390T2 (hu) 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
CN115948467A (zh) 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
IL314272A (en) 2016-05-18 2024-09-01 Hookipa Biotech Gmbh Three-segmented PICHINDE viruses as vaccine vectors
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
US20220380805A1 (en) 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
BR112022024404A2 (pt) 2020-05-29 2023-02-07 Hookipa Biotech Gmbh Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus
BR112023019365A2 (pt) 2021-03-23 2023-12-26 Hookipa Biotech Gmbh Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit

Also Published As

Publication number Publication date
CN101918565B (zh) 2014-04-30
US10655145B2 (en) 2020-05-19
CN103993012A (zh) 2014-08-20
EP2238255B1 (en) 2013-09-11
CN101918565A (zh) 2010-12-15
DK2604695T3 (da) 2023-01-16
US20220315951A1 (en) 2022-10-06
ES2438773T3 (es) 2014-01-20
US20100297172A1 (en) 2010-11-25
HUE061060T2 (hu) 2023-05-28
EP4186978A1 (en) 2023-05-31
US20190062784A1 (en) 2019-02-28
CA2744910A1 (en) 2009-07-09
US8592205B2 (en) 2013-11-26
JP5642556B2 (ja) 2014-12-17
EP2604695B1 (en) 2022-11-16
ES2937147T3 (es) 2023-03-24
DK2238255T3 (da) 2013-11-18
US9944952B2 (en) 2018-04-17
US11401528B2 (en) 2022-08-02
JP2014239688A (ja) 2014-12-25
JP2017079738A (ja) 2017-05-18
FI2604695T3 (fi) 2023-02-16
SI2604695T1 (sl) 2023-03-31
WO2009083210A1 (en) 2009-07-09
LT2604695T (lt) 2022-12-12
JP2011507536A (ja) 2011-03-10
CN103255169A (zh) 2013-08-21
US12227755B2 (en) 2025-02-18
HRP20221475T3 (hr) 2023-01-06
US20250369015A1 (en) 2025-12-04
CN103993012B (zh) 2023-01-10
PT2604695T (pt) 2022-12-07
CA2744910C (en) 2018-01-30
EP2238255A1 (en) 2010-10-13
PL2238255T3 (pl) 2014-02-28
US20160194663A1 (en) 2016-07-07
JP6227094B2 (ja) 2017-11-08
US20140050760A1 (en) 2014-02-20
HK1151829A1 (zh) 2012-02-10
EP2604695A1 (en) 2013-06-19
US20210071198A1 (en) 2021-03-11
US9309289B2 (en) 2016-04-12

Similar Documents

Publication Publication Date Title
PL2604695T3 (pl) Cząstka arenawirusa z defektem replikacji
EP2110390A4 (en) POLYMERIZABLE COMPOSITION
LU92600I2 (fr) Sovaldi (sofosbuvir)
PL3395876T3 (pl) Nowe nanocząstki
EP2114498A4 (en) INHALER
EP2142239A4 (en) INHALATION DEVICE
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
HRP20170963T1 (hr) Modificirani saharidi
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0811433A2 (pt) compostos do tipo triazolil aminopirimidina
BRPI0812840A2 (pt) 2-imidazolinas
AT505058A3 (de) Türschliesssystem
BRPI0812994A2 (pt) Microbiocidas
DK2033675T3 (da) Inhalationsapparat
BRPI0816450A2 (pt) Fungicidas
DE602007010428D1 (de) Teilcheneingeschlossener nanoschalter
BRPI0814248A2 (pt) Inalador
DE112008001216A5 (de) Magnetronplasmaanlage
BRPI0814814A2 (pt) Inalador
DE102007038931A8 (de) Fadenlagennähwirkstoffe
EP2202304A4 (en) MODIFIED CREATININE AMIDOHYDROLASE
AT9563U3 (de) Wirbelsäulenzuggurtung